Actively Recruiting
Phase 1 Study of IBI363 With Bevacizumab or Furuitinib for Adults With Advanced Colorectal Cancer
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-02-12
260
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of IBI363 combined with either Bevacizumab or Furuitinib in adults with advanced colorectal cancer who have progressed on or are unsuitable for standard therapies. This Phase 1 study focuses on understanding how these drug combinations work together in this patient population and is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Participants receive one of two treatment combinations IBI363 with Bevacizumab or IBI363 with Furuitinib. IBI363 is given by intravenous injection every two or three weeks, while Bevacizumab is administered intravenously and Furuitinib is taken orally. The study includes two groups receiving these combinations, with careful monitoring throughout the treatment period. During the study, participants will be closely monitored for adverse events, treatment responses, and disease control up to two years. Assessments include tracking treatment-emergent side effects, objective response rate, time to response, duration of response, progression-free survival, and overall survival. Participants will have regular visits to evaluate their health, tumor status, and any side effects, ensuring thorough safety and efficacy data collection over the study period.
CONDITIONS
Brief Title
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Research Team
Y
yanxi pu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here